PFNX News and Press, Pfenex Inc. From 02/16/20

Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 144 weeks of public selections as part of this ongoing live forward-testing. In...

Curaleaf (CURA CN) initiated with Neutral rating and C$11.40 (41% upside) price target at Cantor Fitzgerald. U.S. ticker: ( OTCPK:CURLF ). More news on: Curaleaf Holdings, Inc., Pfenex Inc., Trulieve Cannabis Corp., Healthcare stocks news, Stocks on the move, , Read more ...

Investing in companies with superior growth can lead to outstanding returns over the long term. However, picking the best growth stocks is easier said than done, and a good idea without the right implementation can do more harm than good. This is especially true among growth stocks because the...

Gainers: CHS   +26.9% . DBVT   +21.6% . AGTC   +13.9% . NNVC   +10.3% . OTCQX:AKOM   +9.1% . More news on: Chico's FAS, Inc., DBV Technologies S.A., Applied Genetic Technologies Corporation, Stocks on the move, , News on ETFs Read more ...

SAN DIEGO, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that Serum Institute of India Private Limited (Serum Institute) achieved World Health Organization (WHO) prequalification for Pneumosil, a 10-valent pneumococcal conjugate vaccine. Pneumosil conta...

Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 138 weeks of public selections as part of this ongoing live forward-testing. In...

The company Pfenex ( PFNX ) is a 'development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology to develop and improve protein therapies for unmet patient needs.' The company has made great progress since my first article, entitled ' Pfenex: A Buy...

SAN DIEGO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that it has earned a $15 million development milestone under its development and license agreement with Jazz Pharmaceuticals plc. The milestone is associated with process development activities fo...

Introduction The Weekly Breakout Forecast continues my doctoral research analysis on multiple discriminant analysis ((MDA)) breakout selections over more than five years. This subset of the different portfolios I regularly analyze has now reached 135 weeks of public selections as part of t...

SAN DIEGO, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its Pf ēnex Expression Technology® to develop and improve protein therapies for unmet patient needs. Using the patented Pf ...